Valuation: Sangamo Therapeutics, Inc.

Market Cap 47.23M 42.4M 38.69M 35.37M 66.7M 4.43B 68.84M 467M 186M 2.37B 177M 173M 7.48B P/E 2024
-2.1x
P/E 2025 -0.96x
Enterprise Value 53.08M 47.64M 43.48M 39.75M 74.96M 4.98B 77.37M 525M 209M 2.66B 199M 195M 8.41B EV / Sales 2024
3.49x
EV / Sales 2025 3.72x
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 week-1.72%
Current month-1.72%
1 month-18.57%
3 months+1.79%
6 months+12.76%
Current year-72.86%
1 week 0.07
Extreme 0.07
0.12
1 month 0.01
Extreme 0.01
0.15
Current year 0.01
Extreme 0.01
0.6
1 year 0.01
Extreme 0.01
0.6
3 years 0.01
Extreme 0.01
3.18
5 years 0.01
Extreme 0.01
10.78
10 years 0.01
Extreme 0.01
27.5
Manager TitleAgeSince
Chief Executive Officer 63 2016-05-31
Director of Finance/CFO 47 2026-02-02
Chief Tech/Sci/R&D Officer - 2023-05-28
Director TitleAgeSince
Chairman 70 2017-05-31
Director/Board Member 63 2016-05-31
Director/Board Member 68 2016-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/25/26 Tax

General Counsel

-4,036 0.0010%
5/25/26 Tax

Executive/Senior Manager

-4,036 0.0010%
5/25/26 Tax

Chief Executive Officer

-12,613 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.72%-75.84%-72.86% 47.23M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.02%+2.21%+36.68%+160.10% 40.68B
Weighted average by Cap. +0.65%+3.07%+49.89%+165.85%

Financials

2024 2025
Net sales 57.8M 51.89M 47.35M 43.28M 81.63M 5.43B 84.25M 572M 228M 2.9B 217M 212M 9.16B 39.55M 35.5M 32.4M 29.62M 55.86M 3.71B 57.65M 391M 156M 1.98B 148M 145M 6.26B
Net income -97.94M -87.92M -80.24M -73.34M -138M -9.2B -143M -969M -386M -4.91B -368M -360M -15.51B -123M -110M -101M -92.06M -174M -11.54B -179M -1.22B -484M -6.16B -461M -452M -19.47B
Net Debt -11.35M -10.19M -9.3M -8.5M -16.03M -1.07B -16.55M -112M -44.74M -569M -42.61M -41.69M -1.8B 5.85M 5.25M 4.79M 4.38M 8.26M 549M 8.52M 57.83M 23.04M 293M 21.95M 21.48M 926M
Projected Income Statement - Annual - Sangamo Therapeutics, Inc.
Logo Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.
Employees
142
Date Price Change Volume
26-11-06 US$0.1140 0.00% 474,515
26-11-05 US$0.1140 -0.87% 2,002,507
26-11-04 US$0.1150 -1.71% 874,057
26-11-03 US$0.1170 +1.74% 559,058
26-11-02 US$0.1150 -0.86% 140,408
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Sangamo Therapeutics, Inc.

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sangamo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SGMOQ Stock